On Wednesday, January 26, 2022, the U.S. Food and Drug Administration (FDA) approved tebentafusp-tebn for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Read Immunocore's announcement.
Posted 1/26/2022
In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.
